Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.
about
Optimal Use of Vaccines for Control of Influenza A Virus in SwineAge at Vaccination and Timing of Infection Do Not Alter Vaccine-Associated Enhanced Respiratory Disease in Influenza A Virus-Infected Pigs.Viral vector-based influenza vaccines.Vaccine development for protecting swine against influenza virus.Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.Options and obstacles for designing a universal influenza vaccineAnimal models for influenza viruses: implications for universal vaccine developmentVaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model.Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.Partial Protection against Porcine Influenza A Virus by a Hemagglutinin-Expressing Virus Replicon Particle Vaccine in the Absence of Neutralizing Antibodies.Salmonella Vaccination in Pigs: A Review.Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs.Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View
P2860
Q26783503-6E91BB5F-6D20-4A2E-88B0-3871574B1768Q30386279-A739C1A1-1929-446D-9FEE-5DDE561AC973Q30390938-C685D6C3-FD67-4955-825A-3D72B4E3A1FFQ30424943-35C14987-5C4D-4287-ADBE-88CC75EBC84DQ34059627-4B5F6268-CCCF-4E6F-A30A-6D5D2FAE6D04Q34102290-DEC423EF-7AF4-4C44-96F7-8E30714DB114Q34809686-1F00F398-FB51-48CA-933F-18BB137D36D3Q34976021-D7C75107-EDD0-4ABD-90B7-9A07723D9967Q36076112-09EAF9BC-5C32-4E95-A255-83A251FFC349Q36087562-C7A505EC-ADA7-4114-AF0A-E20639C7E7BDQ38436945-5495B978-64F4-49D5-8250-F577333DB750Q38725470-DC99A070-4F33-4B24-B002-CA4644832AB3Q41695836-F5192AA7-2EB5-4CA9-8877-2492D8F13F5BQ50308620-3ADAF93C-545E-4407-A99C-84EC885A5A59Q56536297-6FEE4675-7043-49B1-9FC6-A9B17353CDE0
P2860
Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Intranasal vaccination with re ...... eterologous challenge in pigs.
@ast
Intranasal vaccination with re ...... eterologous challenge in pigs.
@en
type
label
Intranasal vaccination with re ...... eterologous challenge in pigs.
@ast
Intranasal vaccination with re ...... eterologous challenge in pigs.
@en
prefLabel
Intranasal vaccination with re ...... eterologous challenge in pigs.
@ast
Intranasal vaccination with re ...... eterologous challenge in pigs.
@en
P2093
P2860
P356
P1476
Intranasal vaccination with re ...... heterologous challenge in pigs
@en
P2093
Amy L Vincent
Andrea A Gambotto
Crystal L Loving
Douglas R Braucher
Jamie N Henningson
Julia Steitz
P2860
P304
P356
10.1128/CVI.00315-12
P577
2012-08-29T00:00:00Z